OR WAIT null SECS
Catalent adds two softgel facilities and packaging capabilities with acquisition of Canada-based Accucaps.
Catalent announced on Nov. 28, 2016 that it has agreed to acquire Accucaps Industries Limited, a Canada-based developer and manufacturer of over-the-counter, high potency, and conventional pharmaceutical softgels.
Upon completion of the acquisition, Accucaps’ more than 500 employees at its two facilities in Windsor and Strathroy, Ontario, will join Catalent’s global network of 11 softgel technologies facilities. The Accucaps facilities house sizeable blistering, bottling, and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent’s, the company reports.
“Significant investments already made by Accucaps align well with Catalent’s own strategic goals, to offer our customers access to more products, capacity, and integrated solutions for differentiated products and better treatments,” said Aris Gennadios, Catalent’s President of Softgel Technologies, in a press statement.
Financial details of the transaction have not been disclosed. The acquisition is subject to Canadian governmental approval.